IDT Australia Limited · ASX:IDT

IDT Australia — Shareholder Meeting (November 2026)

14 slides from IDT Australia's shareholder meeting presentation, Nov 18, 2026

  1. Slide 1: From Turnaround to Growth

    rsonal use only ANNUAL GENERAL MEETING · 2026 From Turnaround to Growth November 2026 Advanced Manufacturing for Breakthrough Medicines ASX: IDT

  2. Slide 2: Disclaimer and Important Notices

    Disclaimer and Important Notices This presentation has been prepared by IDT Australia Limited ACN 006 522 970 (Company). It This presentation may contain forward-looking statements, guidance, forecasts, estimates, rsonal use only contains general background information only which is current at the d

  3. Slide 3: Building on the Momentum

    Building on the Momentum From turnaround to growth FY26 RESULTS HIGHLIGHTS FY27 GUIDANCE rsonal use only REVENUE, 3 VERTICALS The Turnaround REVENUE, 3 VERTICALS EBITDA loss narrowed 85% FY26 FY27 –$6.3M ▲ 13% - 19% $16.8M $19.0M - $20.0M ▲ 16.5% YoY EBITDA –$0.9M FY26: $16.8M | FY25: $14.4M FY26 FY

  4. Slide 4: Business Growth Drivers

    Business Growth Drivers Why we are more confident than 12 months ago rsonal use only 1 2 3 4 5-Year Return to Profitability Radiopharmaceutical ~$7M Plant Upgrade $50M Revenue Pathway Contract Signed Positive EBITDA forecast from New contract from existing Modernising plant and Clear strategy to ach

  5. Slide 5: Objectives of Business Reset Strategy

    Objectives of Business Reset Strategy Why we reset the business rsonal use only Sustainable Growth Reduce Revenue Volatility Focus on operating profits, margins and cost Building a bank/backlog of work to fill gaps when control instead of revenue growth at any cost client contracts get unexpectedly

  6. Slide 6: End-to-End Manufacturing Advantage

    End-to-End Manufacturing Advantage One of the few Australian CDMOs that can support customers from API through to finished -dose rsonal use only Active Pharmaceutical Solid Oral Manufacturing Sterile Manufacturing Ingredient (API) Full-year revenue up 29% to $5.4M Full-year revenue up 52% to $5.5M F

  7. Slide 7: Multiple Markets Supporting Growth

    Multiple Markets Supporting Growth IDT’s $50M target reflects <0.038% of serviceable addressable market (SAM) rsonal use only Total SAM IDT is a specialist, agile CDMO focused on complex Small-Molecule API, and Sterile & Non-Sterile manufacturing — delivering the agility and responsiveness required

  8. Slide 8: Upgrade Program Progressing to Plan

    Upgrade Program Progressing to Plan ~$7M business investment is fully funded New Sterile Manufacturing Line Solid oral dose upgrade rsonal use only Isolator Technology — the global gold standard for Grade A aseptic fill-finish Tablet Press, Coating, Solids Handling & Complete Bottle Line • Enables c

  9. Slide 9: Sterile Manufacturing: The Largest Growth Opportunity

    Sterile Manufacturing: The Largest Growth Opportunity Competitive advantage as end -to-end specialist & agile CDMO rsonal use only APAC is fastest growing region at 12.3% CAGR (vs. ROW New sterile manufacturing line: 11.2%) Isolator-based aseptic fill-finish system Strong pricing power due to lack o

  10. Slide 10: Pathway to $50M Revenue

    Pathway to $50M Revenue Why we believe the target is achievable Strategic positioning rsonal use only Positioning 01 Specialist in complex small-molecule API and sterile & non-sterile manufacturing — an agile solution for emerging biotech and pharma. Customer Expansion Existing customer expansion 02

  11. Slide 11: Outlook and Highlights

    Outlook and Highlights Return to sustained profitability from FY27 rsonal use only From Turnaround to Growth Improving Earnings Quality • Improved operating leverage • Increased level of repeat & follow-on work via end-to-end services • FY27 Forecast Revenue – $19.0M - $20.0M (up 19%-25%) • Deepenin

  12. Slide 12: Board of Directors

    Board of Directors Experienced board and leadership team rsonal use only An experienced and accomplished professional in the health industry with over 17 years' board experience Mark Simari across a diverse range of organisations. Former managing director and co-founder of Paragon Care (2008– Execut

  13. Slide 13: Investor & Media Enquiries

    rsonal use only INVESTOR & MEDIA ENQUIRIES Brendon Lau brendon@vantagepointpartners.com.au +61 409 341 613 Advanced Manufacturing for Breakthrough Medicines

  14. Slide 14: References & Definitions

    Appendix References & Definitions rsonal use only REFERENCES DEFINITIONS 1 Mordor Intelligence — Active Pharmaceutical Ingredients (API) market Total Addressable Market mordorintelligence.com/industry-reports/global-active-pharmaceutical-ingredients-api-market TAM Total market demand — the maximum r

IDT Australia — Shareholder Meeting (November 2026) on 6ix